Through the PPI network map, we found that there were 28 key targets of ADI in the treatment of NSCLC, including 6 key genes that existed in the main signaling pathways, which were AKT1, TP53, CASP3, MAPK1, MMP9, and PTGS2. This evidence concerns the gene CASP3 and non-small cell lung carcinoma.